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Introduction
Use of complementary and alternative medicines (CAMs) 
is widespread in patients with chronic diseases, particularly 
cancer. Although the rate of use varies depending on patient 
demographics and cancer type, it has been estimated that 
around half of all patients use CAM therapy in Western 
countries.1 Patients with breast cancer are among the most 
likely users of CAMs, with a recent study reporting that 
67% of women initiated some form of CAM following a 
diagnosis of breast cancer.2
Despite the high prevalence of CAM use in patients with 
cancer, clinical evidence of their benefit is sparse, and 
although they are often assumed to be safe with regard to 
concurrent therapies, few studies have been carried out to 
demonstrate this.3,4 Furthermore, oncologists are often 
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Abstract
Background: Although the use of complementary and alternative medicines is widespread in cancer patients, clinical 
evidence of their benefits is sparse. Furthermore, while they are often assumed to be safe with regard to concurrent 
use of anticancer therapies, few studies have been carried out to investigate possible interactions. Fucoidans are a 
group of sulfated carbohydrates, derived from marine brown algae, which have long been used as dietary supplements 
due to their reported medicinal properties, including anticancer activity. The aim of this study was to investigate the 
effect of co-administration of fucoidan, derived from Undaria pinnatifida, on the pharmacokinetics of 2 commonly used 
hormonal therapies, letrozole and tamoxifen, in patients with breast cancer. Methods: This was an open label non-
crossover study in patients with active malignancy taking letrozole or tamoxifen (n = 10 for each group). Patients took oral 
fucoidan, given in the form of Maritech extract, for a 3-week period (500 mg twice daily). Trough plasma concentrations 
of letrozole, tamoxifen, 4-hydroxytamoxifen, and endoxifen were measured using HPLC-CAD (high-performance liquid 
chromatography charged aerosol detector), at baseline and after concomitant administration with fucoidan. Results: No 
significant changes in steady-state plasma concentrations of letrozole, tamoxifen, or tamoxifen metabolites were detected 
after co-administration with fucoidan. In addition, no adverse effects of fucoidan were reported, and toxicity monitoring 
showed no significant differences in all parameters measured over the study period. Conclusions: Administration of 
Undaria pinnatifida fucoidan had no significant effect on the steady-state trough concentrations of letrozole or tamoxifen 
and was well tolerated. These results suggest that fucoidan in the studied form and dosage could be taken concomitantly 
with letrozole and tamoxifen without the risk of clinically significant interactions.
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unaware that their patients are taking CAMs.5-7 This is par-
ticularly concerning considering the narrow therapeutic 
index of many anticancer agents, where small changes in 
pharmacokinetics could potentially lead to significant 
adverse or subtherapeutic effects.
Fucoidans are a group of sulfated carbohydrates derived 
from marine brown algae (eg, Fucus vesiculosus, Cladosiphon 
okamuranus, Laminaria japonica, and Undaria pinnatifida) 
and have long been used as dietary supplements in Asia for 
medicinal purposes. The reported benefits of fucoidan extracts 
include anticancer, anticoagulant, anti-inflammatory, antivi-
ral, and immunomodulating activities.8 The anticancer activ-
ity of fucoidans is well documented, with the first reports 
appearing in the 1980s.9,10 Since then, there have been numer-
ous studies to show fucoidans can both directly and indirectly 
induce apoptosis in vitro in a number of different cancer cells 
lines.11-17 In recent years, there has been a growing body of 
evidence to suggest that the in vitro anticancer activity of 
fucoidans can be translated in vivo in animal models.17-22 One 
study investigated orally administered fucoidan (derived from 
Cladosiphon sp) in patients with colorectal cancer and found 
significantly reduced fatigue and increased tolerability to che-
motherapy.23 Patients taking fucoidan also had prolonged sur-
vival; however, this was not statistically significant in the 
small sample studied. Fucoidan is included in various dietary 
supplements that are sometimes taken by cancer patients. The 
possibility for developing fucoidan as an adjunct or sole anti-
cancer agent has been discussed.24,25
There are only a few studies regarding the potential sys-
temic availability of fucoidan after oral administration. 
Clinical studies indicate only very low absorption,26,27 in 
line with that of other carbohydrates, such as chondroitin 
sulfate. Animal studies show that there is potential for some 
fucoidan uptake and localization in organs and tissues.28 
There are currently no validated methods for the measure-
ment of serum levels of fucoidan, so they were not assessed 
in the study described here.
There appear to be no studies that have investigated the 
potential pharmacokinetic interactions between fucoidans and 
conventional cancer therapies. The aim of this study was to 
investigate the effect of Undaria fucoidan co-administration on 
the pharmacokinetics of 2 commonly used hormonal therapies, 
letrozole and tamoxifen, in patients with breast cancer. Plasma 
concentrations are reported for letrozole, tamoxifen, and 2 
active metabolites of tamoxifen, 4-hydroxytamoxifen and 
endoxifen (4-hydroxy-N-desmethyl-tamoxifen), before and 
after administration with fucoidan. In addition, patients were 
monitored for potential adverse effects.
Methods
Patients
This clinical study was carried out at the Royal Hobart 
Hospital, Hobart, Australia. Participants had active breast 
cancer and had been taking a stable once-daily oral dose of 
either letrozole (2.5 mg) or tamoxifen (20 mg) for a mini-
mum of 4 weeks prior to the study, to ensure steady state 
had been achieved, with at least 3 weeks of therapy remain-
ing in their treatment course. The patients were not random-
ized but were already taking their medication as advised by 
their physician. Other inclusion criteria were as follows: 
aged ≥18 years; able to complete documentation of the 
treatment and adverse events, and attend follow-up; and 
able to swallow capsules whole. Patients were excluded if 
they met any of the following criteria: reluctance or inabil-
ity to cease other CAM at least a week prior to trial com-
mencement; ECOG (Eastern Cooperative Oncology Group) 
performance of ≥3; life expectancy of ≤12 weeks; impaired 
hematopoietic (white blood cells < 3.0 × 109/L, absolute 
neutrophil count < 1.5 × 109/L, platelet < 100 × 109/dL), 
renal (glomerular filtration rate < 50 mL/min), or hepatic 
function (either aspartate transaminase/alanine transami-
nase > 2.5 ULN, or > 5 × ULN in case of liver metastases, 
or bilirubin > 1.5 × ULN); pregnancy or lactation; cerebral 
or leptomeningeal metastases that were unstable in spite of 
appropriate therapy; serious intercurrent illness; major sur-
gery within 2 weeks prior to study commencement; concur-
rent radiotherapy; bowel obstruction; documented allergy 
to fucoidan; concurrent warfarin therapy; and participation 
in trials of other pharmacological agents during the time of 
this study.
Study Design and Procedures
Fucoidan was given in the form of Maritech extract 
(Marinova Pty Ltd, Hobart, Australia), which was derived 
from Undaria pinnatifida using the proprietary Maritech 
extraction process. The total daily dose of Maritech extract 
was 1000 mg, given as one 500 mg capsule in the morning 
and at night after food. The study medication was manufac-
tured under the code of Good Manufacturing Practice. The 
Maritech extract was standardized to 88.9% fucoidan 
content.
At baseline, patients underwent a physical examination 
and demographics were collected. Blood samples were also 
collected for toxicity and pharmacokinetic analysis. In addi-
tion to their existing hormonal therapy, patients then com-
menced fucoidan administration for a 3-week period. At the 
end of the dosing interval, patients underwent the same 
physical examination, and blood samples were collected for 
toxicity and pharmacokinetic analysis.
Adverse drug reactions of letrozole and tamoxifen were 
graded using the NCI Common Terminology Criteria for 
Adverse Events Version 4.0 for hematological and nonhe-
matological toxicities. Adherence to fucoidan was mea-
sured by telephone calls and inspection of returned bottles 
on completion of the study.
The patients were asked about any new symptoms or 
changes since the introduction of fucoidan. The research 
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nurse noted comments by subjects. The study was approved 
by the Human Research Ethics Committee (Tasmania) 
Network, and all patients provided written informed con-
sent prior to study entry.
Materials
Reference standards of letrozole, tamoxifen, 4-hydroxy-
tamoxifen, and endoxifen were purchased from Sigma-
Aldrich (Castle Hill, New South Wales, Australia). 
Solid-phase extraction cartridges were purchased from 
Waters (Waters Corporation, Milford, MA). Water was pre-
pared in-house using a Milli-Q gradient water purification 
system (Millipore, Bedford, MA), and all other solvents and 
chemicals were of high-performance liquid chromatography 
(HPLC) or analytical grade.
Sample Collection
Pre and post extract blood was collected in 2 ethylenediami-
netetraacetic acid tubes (18 mL of blood per participant). 
One sample was sent to a NATA (National Association of 
Testing Authorities, Australia) accredited laboratory 
(Hobart Pathology, Tasmania) to assess hematological and 
biochemical toxicity, which was determined using the fol-
lowing tests: urea, electrolytes, and creatinine; liver func-
tion tests (LFTs); and full blood count. All hematological 
toxicity tests were performed according to NATA guidelines 
using standardized methods. The second blood sample was 
centrifuged within 30 minutes of collection at 2000g for 10 
minutes at room temperature. The plasma was transferred 
using a disposable pipette into cryovials and stored in a 
−20°C freezer for later analysis of letrozole, tamoxifen, and 
tamoxifen metabolites.
Sample Preparation for Letrozole, Tamoxifen, 
and Tamoxifen Metabolite Analysis
Plasma samples (5 mL) were first protein-precipitated using 
ethanol (45 mL). The samples were vortex-mixed and kept 
overnight at −20°C, followed by centrifugation at 12 000g 
for 15 minutes. The resultant supernatant was concentrated 
on a miVac DNA centrifugal concentrator (Genevac Ltd, 
Suffolk, UK) to 2 mL. Ammonia buffer solution (1 mL, 
0.025 mM, pH 10) was then added and samples were fur-
ther extracted through solid-phase extraction cartridges. 
Solid-phase extraction cartridges were conditioned with 
methanol (1 mL), followed by water (2 mL), and the sam-
ples were loaded onto the cartridges and eluted under vac-
uum. Cartridges were again washed with water (2 mL) 
followed by extraction using methanol (4 × 250 µL). The 
resultant eluate was centrifuged at 12 000g for 10 minutes 
and subjected to HPLC analysis. All plasma samples were 
prepared in triplicate and each triplicate was analyzed in 
duplicate.
HPLC-CAD (Charged Aerosol Detector) 
Conditions
Chromatographic analyses for letrozole, tamoxifen, 
4-hydroxytamoxifen, and endoxifen were performed on a 
HPLC system (Thermo Fisher Scientific, North Ryde, New 
South Wales, Australia) consisting of a HPG-3400RS binary 
separation pump, WPS-3000TRS auto-sampler, and a TCC-
3000RS column thermal compartment. The system was con-
nected to Corona Ultra RS charged aerosol detector (Thermo 
Fisher Scientific), using a nitrogen flow of 35 psi and nebu-
lizer temperature of 30°C. Instrument control and data 
acquisition were performed using Chromeleon software.
Separation of analytes was achieved using an Acquity 
UPLC HSS C
18
 SB column (100 × 2.1 mm internal diame-
ter, 1.8 µm particle size; Waters, Milford, MA). The mobile 
phase consisted of 0.1% trifluoroacetic acid in water 
(mobile phase A) and 0.1% trifluoroacetic acid in acetoni-
trile (mobile phase B), with a flow rate of 1 mL/min and 
gradient elution of mobile phase B from 25% to 55% over 
45 minutes. The temperature of the column and sample 
compartments was set at 40°C and 5°C, respectively, with 
an injection volume of 50 µL.
Calibration standards for letrozole, tamoxifen, 4-hydroxy-
tamoxifen, and endoxifen were prepared in triplicate by 
spiking control plasma samples with standard analyte solu-
tions and extracted in the same way as that detailed above 
for the test plasma samples. Calibration curves were linear 
over a concentration range of 15.6 to 500 ng/mL for letro-
zole and tamoxifen, and 1.56 to 50 ng/mL for 4-hydroxy-
tamoxifen and endoxifen. Assay performance was assessed 
over 5 days (n = 6) at 3 concentrations for all analytes. Intra- 
and interday accuracy, precision, and reproducibility (% 
RSD) were found to be less than 9.1%, 10.7%, and 1.9%, 
respectively, for all analytes, and the extraction recovery of 
analytes from plasma samples was found to be at least 89.6% 
(range = 89.6% to 95.2%).
Data Analysis
Steady-state trough concentrations of letrozole, tamoxifen, 
4-hydroxytamoxifen, and endoxifen were compared before 
and after fucoidan treatment, using a paired t test. A P value 
of less than .05 was considered significant.
Results
Twenty patients, all female, were included in this study; 10 
were taking letrozole and 10 were taking tamoxifen. The 
median age of the participants was 59 years, with a range of 
43 to 76 years. Patient demographics are summarized in 
Table 1. All participants successfully completed the study. 
There was a variety of self-reported subjective adverse 
events, including nausea, diarrhea, constipation, and head-
ache. All were mild and transient. Conversely, 4 patients, 2 
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taking letrozole and 2 taking tamoxifen, reported a reduction 
in their bone and muscular pain during the 3-week fucoidan 
treatment period, as detailed in Table 2. There was no sig-
nificant change in blood parameters (LFTs, renal function 
tests, and hematology) over the study period in all patients 
(data not shown), with one exception. Prior to fucoidan 
treatment, the LFTs for this patient were mildly abnormal 
(γ-glutamyl transferase [GGT] 140 units) and after 3 weeks 
of fucoidan, her GGT levels remained elevated (174 units). 
The cause of the raised GGT levels was not known; specifi-
cally, there was no evidence of hepatic metastases.
Individual trough concentrations of letrozole, tamoxifen, 
4-hyroxytamoxifen, and endoxifen before and after 3 weeks of 
treatment with fucoidan are shown in Figure 1. No significant 
differences in these concentrations were detected, and the 
results are summarized in Table 3. Normalizing for body 
weight, height, and age had no influence on drug or metabolite 
levels and did not alter the statistical outcome (data not shown).
Discussion
The use of CAMs in conjunction with standard cancer ther-
apies has become commonplace over the past 20 years. 
Despite this, clinical evidence of their safety when used 
with conventional therapies remains scarce. In addition, due 
to the “natural” origin of many CAMs, it is often assumed 
by patients that these products are safe and nontoxic, and 
therefore fail to mention CAM use to their oncologist.3,4,7,29 
As evidenced by many potent conventional therapies, 
including anticancer agents, being derived from natural 
products (eg, digoxin, morphine, docetaxel, topotecan) and 
with the potential to produce serious toxicity if used inap-
propriately, the assumption of CAM safety can be errone-
ous. Well-conducted trials investigating the effect of CAMs 
on conventional drugs are warranted to generate evidence-
based information on the safe combined use of these agents.
There is an abundance of in vitro studies, and an increas-
ing number of in vivo studies in animal models, showing the 
anticancer activity of the commonly used CAM, fucoidan.8 
As a result, research interest and a wider public awareness of 
its use as a potential anticancer agent has grown in recent 
years. A number of studies have demonstrated that fucoidan, 
irrespective of source, does not appear to exert any toxic 
effects in animals or humans when given as monotherapy, 
after either acute or chronic exposure. For instance, doses of 
up to 2000 mg/kg/day have been administered to rats with 
no adverse effects.30 Clinical trials in humans have reported 
no adverse effects at oral doses of 1 g daily for 12 weeks,31 
or 3 g daily for 12 days.32 However, there have been no stud-
ies to date to investigate if fucoidan has any effect on the 
pharmacokinetics of conventional cancer therapies.
Letrozole and tamoxifen were studied as they are among 
the most commonly utilized drugs in breast cancer patients. 
While there was no reason to think that fucoidan would inter-
fere with hormonal therapy, there was a possibility that fucoi-
dan would interfere with gastrointestinal absorption of the 
drugs, due to being a poorly absorbed and large molecular 
weight carbohydrate. However, this study showed that the co-
administration of Undaria fucoidan did not significantly 
influence the steady-state trough plasma concentrations of the 
hormonal therapies, letrozole and tamoxifen, in patients with 
breast cancer. It also showed no significant differences in the 
plasma levels of the active metabolites of tamoxifen, 
4-hydroxytamoxifen and endoxifen, before and after fucoidan 
administration, although a mean decrease of 21% in the level 
of 4-hydroxytamoxifen and a mean increase of 25% in the 
level of endoxifen was observed after fucoidan administration 
(see Figure 1 and Table 3). 4-Hydroxytamoxifen and endoxi-
fen are considerably more potent than tamoxifen.33,34 In the 
case of 4-hydroxytamoxifen, plasma concentrations of this 
metabolite are not thought to correlate with treatment out-
comes in breast cancer,35 and so the reduction observed in this 
study is unlikely to be of clinical significance. On the other 
hand, the long-term benefit of tamoxifen therapy in breast 
cancer is thought to be directly related to maintaining endoxi-
fen plasma concentrations above a threshold level.35,36 
Although the change in endoxifen levels post-fucoidan was 
not statistically significant, further investigation is warranted 
to ascertain if there are any clinical consequences of the 
observed increase in plasma levels. The study was only a 
3-week study, but that is quite sufficient for a drug interaction 
study. This study period is ample given the short half-lives of 
the anticancer drugs examined (ie, any changes in their steady-
state plasma levels would be apparent by that time). Also, any 
potential effect of fucoidan on liver enzymes (whether induc-
ing or inhibiting) would be fully apparent in that timeframe.
There have been a limited number of clinical studies inves-
tigating the effect of other CAMs on the pharmacokinetics of 
anticancer agents.37-42 One noteworthy study by Goey and 
coworkers showed that St John’s wort, commonly used as a 
“natural” antidepressant, significantly increased docetaxel 
clearance through induction of CYP3A4, giving rise to the 
potential for subtherapeutic dosing of this anticancer agent.39 
Table 1. Patient Demographics and Clinical Characteristics.
Letrozole Tamoxifen
Number of patients 10 10
Age at diagnosis (years)
 Median 52 50
 Range 18-75 42-74
Weight (kg)
 Median 83 79
 Range 57-95 51-119
Duration of treatment (months)
 Median 16.5 11.5
 Range 1-84 1-36
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Figure 1. Plasma trough concentrations (ng/mL) of (A) letrozole, (B) tamoxifen, (C) 4-hydroxytamoxifen, and (D) endoxifen before 
and after 3 weeks of fucoidan treatment in individual patients receiving either letrozole (n = 10) or tamoxifen (n = 10).
Table 3. Mean Plasma Trough Concentrations (ng/mL) of Letrozole, Tamoxifen, 4-Hydroxytamoxifen, and Endoxifen, Before and 
After 3 Weeks of Fucoidan Administrationa.
Drug
Plasma Concentration (ng/mL)
Before Fucoidan 
Administration
After Fucoidan 
Administration P Valueb
Letrozole 110.3 ± 38.7 95.5 ± 23.1 .12
Tamoxifen 167.5 ± 43.1 183.4 ± 34.0 .27
4-Hydroxytamoxifen 3.6 ± 1.1 2.8 ± 0.7 .07
Endoxifen 6.2 ± 1.9 7.8 ± 2.1 .09
aN = 10; data are presented as mean ± standard deviation.
bPaired t test.
Table 2. Patients With Reduction in Pain.
Patient Duration of Treatment Age at Diagnosis (Years) Treatment Joint Pain
1 5 Months 49 Letrozole Related to letrozole
2 21 Months 33 Letrozole Related to letrozole
3 6 Months 42 Tamoxifen Related to tamoxifen
4 4 Weeks 58 Tamoxifen History of arthritis
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Garlic has also been shown to exert some inhibitory effects on 
docetaxel clearance; however, the changes reported were 
unlikely to result in any clinically significant consequences.37 
More recently, fish oil was shown to reduce the efficacy of 
cisplatin in tumor-bearing mice due to the presence of a che-
moresistance-inducing fatty acid, raising concerns over the 
use of fish oil and consumption of certain fish by patients 
undergoing chemotherapy.42 Other trials have demonstrated 
no clinically significant interactions between CAMs and anti-
cancer agents; these include Echinacea with docetaxel,38 
ginkgo biloba with letrozole and tamoxifen,40 and milk thistle 
with irinotecan.41 Results from the current study can now be 
added to this small body of evidence to allow more informed 
patient-physician discussions and decisions regarding the use 
of fucoidan with hormonal cancer therapy.
Although biological activity has been reported after oral 
ingestion,8 little research has been carried out to examine the 
absorption and fate of fucoidan and, consequently, the 
mechanisms of any potential interactions remain unknown. 
Fucoidans are large molecular weight polysaccharides, rang-
ing from 10 kDa to 500 kDa, and therefore oral absorption 
and systemic exposure is thought to be low.8 Nevertheless, 
using ELISA techniques, fucoidan has been detected in the 
blood and urine of humans after oral ingestion.26,27 Nagamine 
and co-workers recently demonstrated a dose-dependent 
increase in transport of Cladosiphon okamuranus-derived 
fucoidan across Caco-2 cells, and detected fucoidan in rat 
jejunal and liver cells after oral ingestion.28 These findings 
give rise to the possibility of distribution, metabolism, and 
elimination based drug interactions.
Unlike the docetaxel-St John’s wort interaction, where 
cytochrome P450 enzymes are well known to play a key 
role,43-46 there is no evidence to suggest fucoidan affects the 
drug metabolizing enzymes responsible for the metabolism 
of letrozole or tamoxifen. Letrozole and tamoxifen are 
metabolized by CYP2A6 and CYP2D6, respectively, and 
genetic polymorphisms in these genes result in interindi-
vidual variation in the metabolism of these compounds.47,48 
We did observe a large interpatient variability in drug and 
metabolite levels, which is consistent with other pharmaco-
kinetic studies on letrozole47,49 and tamoxifen.50,51 Fucoidan 
has not been systematically tested against CYP enzymes, 
and the limited evidence from the small sample size in this 
study did not indicate any effect on the CYP enzymes.
In conclusion, administration of fucoidan showed no 
effect on the steady-state plasma concentrations of letrozole 
or tamoxifen and was well tolerated, with patients reporting 
no adverse effects that could be attributed to this dietary 
supplement.
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